Duane Kuentz, MD
Family Medicine · Alliance, OHNPI 1366531071
Payments from drug & device makers
Across 238 payments — averaging $13.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$517
- AbbVie$358
- AstraZeneca$341
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$272
- Lilly USA, LLC$250
- GSK$194
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,25999%
- Education$221%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 57 | $517 |
| AbbVie(2 entities) | 20 | $358 |
| AstraZeneca | 21 | $341 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 15 | $272 |
| Lilly USA, LLC | 17 | $250 |
| GSK | 13 | $194 |
| Johnson & Johnson | 19 | $172 |
| Novartis | 7 | $119 |
| Amarin Pharma, Inc. | 8 | $113 |
| Abbott | 6 | $94 |
| Merck | 6 | $82 |
| Amgen | 5 | $82 |
| Astellas Pharma US Inc | 5 | $77 |
| Novo Nordisk | 5 | $74 |
| Daiichi Sankyo Inc. | 3 | $53 |
| Vertical Pharmaceuticals, LLC | 3 | $52 |
| Sunovion Pharmaceuticals Inc. | 4 | $49 |
| Sumitomo Pharma America, Inc. | 3 | $43 |
| Phathom Pharmaceuticals, Inc. | 3 | $42 |
| Mylan Specialty L.p. | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $32 |
| Avanir Pharmaceuticals, Inc. | 2 | $31 |
| Pulmonx Corporation | 1 | $26 |
| Exact Sciences | 1 | $25 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Viiv Healthcare Company | 1 | $20 |
| Dynavax Technologies Corporation | 1 | $19 |
| Boehringer Ingelheim | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
| Phadia US Inc. | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$3,281 in reported general payments places this provider in the 80th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 71 | $63,487 |
| JardianceEmpagliflozin | 56 | $49,619 |
| XareltoRivaroxaban | 43 | $42,726 |
| FarxigaDapagliflozin Propanediol | 15 | $22,631 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $21,890 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $19,063 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $18,828 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 14 | $13,106 |
| EntrestoSacubitril/Valsartan | 14 | $13,028 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $9,439 |
| RybelsusSemaglutide | 11 | $8,315 |
| Metoprolol Succinate | 314 | $6,015 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 22 | $4,846 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $4,723 |
| Testosterone | 13 | $4,079 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $517 | $63,48771 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $14 | $54,34167 claims |
| Johnson & JohnsonXarelto | $172 | $42,72643 claims |
| MerckJanumet, Janumet Xr | $82 | $31,93427 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $194 | $28,50237 claims |
| AstraZenecaFarxiga | $341 | $22,63115 claims |
| NovartisEntresto | $119 | $13,02814 claims |
| Novo NordiskRybelsus | $74 | $8,31511 claims |
| AbbVieSynthroid | $358 | $1,96760 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Alliance
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.